Rafael Holdings, Inc.

NYSE RFL

Rafael Holdings, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2024

Rafael Holdings, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending October 31, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NYSE: RFL

Rafael Holdings, Inc.

CEO	Mr. William Conkling
IPO Date	March 27, 2018
Location	United States
Headquarters	520 Broad Street
Employees	13
Sector	Real Estate
Industries Health Care REITs Office REITs

Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key trends

Past 5 years